Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Avelox moxifloxacin: Phase II data

In a double-blind, Brazilian Phase II trial in 146 evaluable patients, moxifloxacin plus isoniazid, rifampin and pyrazinamide

Read the full 176 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE